Latest news with #CohanceLifesciences
Business Standard
29-05-2025
- Business
- Business Standard
Cohance Lifesciences consolidated net profit declines 21.29% in the March 2025 quarter
Sales rise 58.95% to Rs 402.02 crore Net profit of Cohance Lifesciences declined 21.29% to Rs 42.01 crore in the quarter ended March 2025 as against Rs 53.37 crore during the previous quarter ended March 2024. Sales rose 58.95% to Rs 402.02 crore in the quarter ended March 2025 as against Rs 252.93 crore during the previous quarter ended March 2024. For the full year,net profit declined 10.79% to Rs 267.87 crore in the year ended March 2025 as against Rs 300.28 crore during the previous year ended March 2024. Sales rose 13.91% to Rs 1197.58 crore in the year ended March 2025 as against Rs 1051.35 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 402.02252.93 59 1197.581051.35 14 OPM % 18.3029.00 - 31.3338.60 - PBDT 78.3888.10 -11 421.41460.27 -8 PBT 51.6070.85 -27 343.92405.67 -15 NP 42.0153.37 -21 267.87300.28 -11
Business Standard
26-05-2025
- Business
- Business Standard
Cohance Lifesciences' API Unit-IV clears USFDA inspection
Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API Unit-IV, located at Plot No. A-21, Road No. 10, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, Telangana, India, from 03 March 2025 to 07 March 2025. The inspection was classified as Voluntary Action Indicated (VAI) and indicates the formal closure of the inspection process by the USFDA.
Business Standard
08-05-2025
- Business
- Business Standard
Suven Pharmaceuticals renamed as Cohance Lifesciences
Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of India (MCA), has approved change of name of the Company from Suven Pharmaceuticals to Cohance Lifesciences, with effect from 07 May 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. "The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world " said Cohance Executive Chairman, Vivek Sharma.
Business Upturn
22-04-2025
- Business
- Business Upturn
Suven Pharmaceuticals gets nod from Department of Pharmaceuticals for foreign investment increase post merger
By Aditya Bhagchandani Published on April 22, 2025, 23:32 IST Suven Pharmaceuticals has received a key regulatory approval from the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, paving the way for an increase in foreign investment in the company following its merger with Cohance Lifesciences. In an exchange filing dated April 22, 2025, the company confirmed that the approval pertains to the potential increase in aggregate foreign investment beyond 74% in Suven Pharmaceuticals, post the implementation of the Scheme of Amalgamation with Cohance Lifesciences. The clearance comes under the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019, and marks another milestone in the merger process. This development follows a series of approvals over the past year, including the shareholders' nod in November 2024 and the sanctioning of the merger by the National Company Law Tribunal (NCLT) in March 2025. The merger's Effective Date will be the opening business hours of the first day of the month following the fulfilment of all final conditions, as laid out in the approved scheme. The company said it will inform the exchanges about the Effective Date once all conditions are completed. Suven Pharmaceuticals emphasized its continued commitment to compliance and growth, as the merger is aimed at creating synergies and expanding capabilities in the pharmaceutical space. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
